# Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

> **NCT03833167** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 450 (actual)

## Conditions studied

- Carcinoma, Squamous Cell

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03833167
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-01
- **Primary completion:** 2024-06-28
- **Final completion:** 2026-01-20
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03833167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03833167, "Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03833167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*